Sorrento Therapeutics (NSDQ:SRNE) said today that its subsidiary Scilex Pharmaceuticals resubmitted the new drug application for its lidocaine patch, ZTlido, to the FDA.
The San Diego, Calif.-based company is developing the drug-device product for the relief of pain associated with post-herpetic neuralgia.
Get the full story at our sister site, Drug Delivery Business News.
The post Sorrento seeks FDA nod for lidocaine patch appeared first on MassDevice.